NCT04319471

Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma

Single Arm, Open, Multicenter Phase II Clinical Study of Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 70 (estimated)
• Sponsor: Fujian Cancer Hospital · Other Government
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study is a randomized, phase II, prospective, multicenter clinical trial to evaluate the efficacy and safety of sufficient chemoradiotherapy plus oral capecitabine/S-1 for 1 year in the treatment of oligometastatic Nasopharyngeal Carcinoma

Conditions

• Nasopharyngeal Carcinoma

Interventions

Type	Name	Description
DRUG	Capecitabine/S-1	Drug: Capecitabine/S-1
DRUG	Chemotherapy	Gemcitabine (1000mg/m2) D1 D8+ nidaplatinum (80-100mg/m2) D2 q3w ×4-6cycle
RADIATION	Head and neck radiotherapy	IMRT is uesd for the synchronous oligometastatic Nasopharyngeal Carcinoma；
OTHER	Local Consolidative Therapy	radiotherapy，surgery or interventional therapy for all metastatic sites.

Timeline

• Start date: 2020-06-01
• Primary completion: 2023-06-01
• Completion: 2023-06-01
• First posted: 2020-03-24
• Last updated: 2020-03-24

Locations

1 site across 1 country: China